Letter to Editor
Volume 10 Issue 3 - 2021
COVID-19: Traditions, Facts and Science
Igor Klepikov*
MD, Professor, Retired, WA, USA
*Corresponding Author: Igor Klepikov, MD, Professor, Retired, WA, USA.
Received: January 06, 2021; Published: February 17, 2021


AP: Acute Pneumonia; COVID-19: Coronavirus Disease; SARS: Severe Acute Respiratory Syndrome; MERS: Middle East Respiratory Syndrome

The problem of AP belongs to the category of those scientific topics that have not been subjected to a serious conceptual revision. Discussions on this topic in recent decades have had a pre-known direction, where the pathogen was assigned the place of the main cause of the disease, and the essence of the dispute was to find the most effective way to neutralize it. The beginning of the COVID-19 pandemic, which gave a stream of patients with monoetiological inflammation and an infinite number of clinical options, did not affect the ideology of the problem and the search for a "pill for pneumonia". "Cognitive bias" with adherence to certain stereotypes and the difficulty of changing attitudes, despite contradictions and facts, are the main obstacles to future promising solutions [1].


  1. I Zagury-Orly and RM Schwartzstein. “Covid-19 A Reminder to Reason”. The New England Journal of Medicine 383 (2020): e12.
  2. Rudan I., et al. “Epidemiology and etiology of childhood pneumonia”. Bulletin of the World Health Organization 86 (2008): 408-416.
  3. WHO Revised global burden of disease 2002 estimates (2004).
  4. https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome
  5. Ruuskanen O., et al. “Viral pneumonia". Lancet9973 (2011): 1264-1275.
  6. Paula Peyrani., et al. “The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance”. Expert Review of Respiratory Medicine 2 (2019): 139-152.
  7. JP Metlay., et al. “On behalf of the American Thoracic Society and Infectious Diseases Society of America. “Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America”. American Journal of Respiratory and Critical Care Medicine 7 (2019): e45-e67.
  8. Rawson TM., et al. “Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing”. Clinical Infectious Diseases (2020): ciaa530.
  9. Beović M., et al. “Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey”. Journal of Antimicrobial Chemotherapy (2020): 326.
  10. Kim D., et al. “Rates of co-infection between SARS-CoV-2 and other respiratory pathogens”. The Journal of the American Medical Association 323 (2020): 2085-2086.
  11. Lipman M., et al. “SARS-CoV-2 pandemic: clinical picture of COVID-19 and implications for research”. Thorax 75 (2020): 614-616.
  12. Alhazzani W., et al. “Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)”. Critical Care Medicine (2020).
  13. Keeley AJ., et al. “Asymptomatic SARS-CoV-2 infection: the tip or the iceberg?” Thorax 75 (2020): 621-622.
  14. Ing AJ., et al. “COVID-19: in the footsteps of Ernest Shackleton”. Thorax 75 (2020): 693-694.
  15. JH Stone., et al. “Efficacy of Tocilizumab in Patients Hospitalized with Covid-19”. The New England Journal of Medicine (2020).
  16. M Ackermann., et al. “Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 (2020).
  17. Martines RB., et al. “COVID-19 Pathology Working Group (2020). Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States”. Emerging Infectious Diseases 9 (2020): 2005-2015.
  18. Igor Klepikov. "Acute pneumonia. New doctrine and first treatment results." LAP-Lambert Academic Publishing (2020).
  19. Xu Chen. “Avoiding Defensive Medicine among Pandemic”. EC Emergency Medicine and Critical Care 12 (2020): 49-53.
  20. VA Simonovich., et al. “A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia (2020).
  21. O Mitjà., et al. “A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 (2020).
  22. WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results (2020).
  23. E Huang and SC Jordan. “Tocilizumab for Covid-19 - The Ongoing Search for Effective Therapies”. The New England Journal of Medicine 383 (2020): 2387-2388.
  24. DA Berlin., et al. “Severe Covid-19”. The New England Journal of Medicine 383 (2020): 2451-2460.
  25. Rwik Sen. “High-throughput approaches of diagnosis and therapies for COVID-19: antibody panels, proteomics and metabolomics”. Future Drug Discovery (2020).
  26. Koeckerling D., et al. “Awake prone positioning in COVID-19”. Thorax Published Online First: 16 (2020).
  27. Thompson AE., et al. “Prone positioning in awake, nonintubated patients with COVID-19 hypoxemic respiratory failure”. JAMA Internal Medicine (2020).
  28. Winearls S., et al. “Early conscious prone positioning in patients with COVID-19 receiving continuous positive airway pressure: a retrospective analysis”. BMJ, Open Respiratory Research 7 (2020): e000711.
  29. Vianello A., et al. “High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection”. Thorax (2020).
  30. DA Berlin and RM Gulick FJ. “Severe Covid-19”. The New England Journal of Medicine (2020).
  31. ML Ranney., et al. “Critical Supply Shortages - The Need for Ventilators and Personal Protective Equipment during the Covid-19 Pandemic”. The New England Journal of Medicine 382 (2020): e41.
  32. Lai J., et al. “Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019”. JAMA Network Open 3 (2020): e203976-e203976.
  33. RE Leiter. “Reentry”. The New England Journal of Medicine (2020).
  34. JN Rosenquist. “The Stress of Bayesian Medicine - Uncomfortable Uncertainty in the Face of Covid-19”. The New England Journal of Medicine 384 (2021): 7-9.
  35. PY Boëlle., et al. “Trajectories of Hospitalization in COVID-19 Patients: An Observational Study in France”. Journal of Clinical Medicine 9 (2020): 3148.
  36. C Salama., et al. “Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia”. The New England Journal of Medicine 384 (2021): 20-30.
  37. Karagiannidis C., et al. “Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study”. The Lancet Respiratory Medicine 8 (2020): 853-862.
  38. Renato Seligman and Beatriz Graeff Santos Seligman. “Pandemic in the 21st Century. The Challenge of COVID-19”. EC Pulmonology and Respiratory Medicine8 (2020): 30-31.
  39. Grasselli G., et al. “Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy”. The Journal of the American Medical Association (2020).
  40. S Richardson., et al. “Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area”. The Journal of the American Medical Association (2020).
  41. Gupta S., et al. “Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19”. JAMA Internal Medicine 11 (2020): 1436-1446.
  42. A Liapikou., et al. “The management of severe community acquired pneumonia in the ICU. June 2014”. Expert Review of Respiratory Medicine 3 (2014): 293-303.
  43. JW Kim., et al. “The Prognostic Factors of Pneumonia with Septic Shock in Patients Presenting to the Emergency Department”. Korean Journal of Critical Care Medicine 4 (2015): 258-264.
  44. P Jason., et al. “Severe community-acquired pneumonia: timely management measures in the first 24 hours”. Critical Care 20 (2016): 237.
  45. A Vidal and L Santos. “Comorbidities impact on the prognosis of severe acute community-acquired pneumonia”. Porto Biomedical Journal6 (2017): 247-346.
  46. A Ceccato and A Torres. “Sepsis and community-acquired pneumonia”. Annals of Research Hospitals 2 (2018): 7.
Citation: Igor Klepikov. “COVID-19: Traditions, Facts and Science”. EC Pulmonology and Respiratory Medicine 10.3 (2021): 50-55.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

May Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the May issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before May 24, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk